Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

Review (18 RCTs; n=7307 patients) found PARP inhibitors significantly increased risk of myelodysplastic syndrome and acute myeloid leukaemia vs placebo (incidence 0.73% vs 0.47%; OR 2.63; 95% CI 1.13–6.14; p=0.026; I2=0%).

The Lancet Haematology